Wyeth Pharmaceuticals (WYE) Submits Marketing Authorization Application to EMEA for PCV13
More News related to WYE
- Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
- Wyeth (WYE) Extends Collaboration Agreement With Trubion Pharmaceuticals (TRBN)
- Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
- Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders
- New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimer's Disease Market
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has submitted a marketing authorization application to the European Medicines Agency for approval to market its investigational 13-valent pneumococcal conjugate vaccine (PCV13) for infants and young children. Wyeth is seeking an indication for the prevention of pneumococcal disease caused by the 13 serotypes included in the investigational vaccine in infants and children from two months to five years of age. The review of the MAA will be coordinated by the EMEA for all 27 countries in the European Union, as well as Norway, Iceland and Liechtenstein.
Wyeth engages in the discovery, development, manufacture, distribution, and sale of pharmaceuticals, consumer healthcare, and animal health products.
Related Categories
Corporate NewsStocks Mentioned
-15.56Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
